Patient enrollment underway in Phase 1/2 clinical trial in patients with advanced gastrointestinal stromal tumors (GIST)

IND application for lead program candidate, THE-630, cleared by U.S. Food and Drug Administration; initiation of Phase 1/2 clinical trial expected between late fourth quarter 2021 and mid-first quarter 2022

Industry veteran brings more than 25 years of R&D and commercialization experience, with a focus on building a patient-centric precision oncology company Interim CEO Iain Dukes, D.Phil., named Executive Chairman

Founded by pioneers of targeted oncology, Theseus is developing best-in-class TKIs to overcome cancer resistance Presentation at AACR highlights THE-630, the Company's next-generation inhibitor for KIT-mutant gastrointestinal stromal tumors (GIST)